Canaccord raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $587 from $526 and keeps a Buy rating on the shares. The firm updated its model to reflec the impending launch of Rezdiffra in the EU as well as coming out of 3Q earnings.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDGL:
- Madrigal price target raised to $568 from $500 at H.C. Wainwright
- Madrigal Pharmaceuticals presents new data on Rezdiffra
- Madrigal’s Earnings Call: Rezdiffra’s Success and Future Outlook
- Madrigal Pharmaceuticals price target raised to $527 from $485 at Citizens JMP
- Madrigal Pharmaceuticals Reports Strong Q3 2025 Growth